Emergen Research, a leading provider of market research solutions, is thrilled to announce the release of its highly anticipated collection of comprehensive market research content. This innovative offering aims to empower businesses across industries with valuable insights and data-driven strategies to drive growth and success.
In today's competitive marketplace, staying ahead of the curve is essential for businesses of all sizes. Understanding consumer behavior, market trends, and emerging opportunities is crucial for making informed decisions and developing effective strategies. Emergen Research recognizes this need and has invested significant resources in developing a cutting-edge market research content library.
The newly launched Molecular Diagnostics Point-of-Care market research content is meticulously crafted by industry experts, leveraging extensive data analysis, and a deep understanding of various markets. This rich collection includes in-depth reports, whitepapers, case studies, trend analyses, and industry insights covering a wide range of sectors, including but not limited to technology, healthcare, finance, consumer goods, and manufacturing.
The global Molecular Diagnostics Point-of-Care (POC) Market was valued at approximately USD 4.8 billion in 2024 and is projected to reach USD 17.1 billion by 2034, growing at a CAGR of 13.5% during the forecast period. The revenue growth in the market is driven by the expanding demand for rapid, decentralized testing platforms capable of delivering laboratory-grade molecular accuracy at the bedside, in clinics, and increasingly, in homecare environments.
The COVID-19 pandemic accelerated the normalization of molecular diagnostics outside centralized labs, with millions of patients worldwide undergoing PCR and isothermal amplification-based tests at pharmacies, airports, workplaces, and even at home. This shift permanently altered both regulatory expectations and consumer confidence in point-of-care molecular platforms, opening the door to broader diagnostic applications across infectious diseases, oncology, and genetic risk screening.
New-generation POC molecular platforms are becoming compact, cartridge-based, and automation-friendly, capable of sample-to-result processing in under 30 minutes. Companies like Cepheid (Xpert), Abbott (ID NOW), BioFire (FilmArray), and Cue Health have already transformed how acute respiratory infections, STIs, and antimicrobial resistance are diagnosed—enabling early treatment initiation, improved patient triage, and better antimicrobial stewardship.
Health systems and payers are increasingly recognizing the economic value of faster diagnostics. Real-time test-and-treat models are helping reduce hospital admissions, prevent outbreaks, and improve therapeutic precision—especially in emergency departments, rural clinics, and outpatient oncology centers.
Regulatory bodies such as the U.S. FDA, EMA, and Health Canada have created emergency use and accelerated review pathways for POC molecular platforms, while telehealth integration and electronic medical record (EMR) compatibility are driving adoption in homecare settings.
With miniaturization, multiplexing, and digital reporting capabilities improving rapidly, point-of-care molecular diagnostics are expected to move beyond infectious disease and into cancer screening, prenatal genetics, and chronic disease monitoring—defining the future of distributed precision diagnostics.
What Questions Should You Ask before Buying a Market Research Report?
- How is the Molecular Diagnostics Point-of-Care market evolving?
- What is driving and restraining the Molecular Diagnostics Point-of-Care market?
- How will each Molecular Diagnostics Point-of-Care submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each Molecular Diagnostics Point-of-Care submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading Molecular Diagnostics Point-of-Care markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the Molecular Diagnostics Point-of-Care projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of Molecular Diagnostics Point-of-Care projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the Molecular Diagnostics Point-of-Care market?
- Where is the Molecular Diagnostics Point-of-Care market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/11
The global Molecular Diagnostics Point-of-Care (POC) Market was valued at approximately USD 4.8 billion in 2024 and is projected to reach USD 17.1 billion by 2034, growing at a CAGR of 13.5% during the forecast period. The revenue growth in the market is driven by the expanding demand for rapid, decentralized testing platforms capable of delivering laboratory-grade molecular accuracy at the bedside, in clinics, and increasingly, in homecare environments.
The COVID-19 pandemic accelerated the normalization of molecular diagnostics outside centralized labs, with millions of patients worldwide undergoing PCR and isothermal amplification-based tests at pharmacies, airports, workplaces, and even at home. This shift permanently altered both regulatory expectations and consumer confidence in point-of-care molecular platforms, opening the door to broader diagnostic applications across infectious diseases, oncology, and genetic risk screening.
New-generation POC molecular platforms are becoming compact, cartridge-based, and automation-friendly, capable of sample-to-result processing in under 30 minutes. Companies like Cepheid (Xpert), Abbott (ID NOW), BioFire (FilmArray), and Cue Health have already transformed how acute respiratory infections, STIs, and antimicrobial resistance are diagnosed—enabling early treatment initiation, improved patient triage, and better antimicrobial stewardship.
Health systems and payers are increasingly recognizing the economic value of faster diagnostics. Real-time test-and-treat models are helping reduce hospital admissions, prevent outbreaks, and improve therapeutic precision—especially in emergency departments, rural clinics, and outpatient oncology centers.
Regulatory bodies such as the U.S. FDA, EMA, and Health Canada have created emergency use and accelerated review pathways for POC molecular platforms, while telehealth integration and electronic medical record (EMR) compatibility are driving adoption in homecare settings.
With miniaturization, multiplexing, and digital reporting capabilities improving rapidly, point-of-care molecular diagnostics are expected to move beyond infectious disease and into cancer screening, prenatal genetics, and chronic disease monitoring—defining the future of distributed precision diagnostics.
Competitive Landscape:
The latest study provides an insightful analysis of the broad competitive landscape of the global Molecular Diagnostics Point-of-Care market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report.
Shift Toward Decentralized, Rapid Diagnostics in Infectious Disease and Emergency Care
The most significant driver of the molecular diagnostics point-of-care (POC) market is the healthcare industry’s shift toward decentralized, rapid testing solutions—particularly in the management of infectious diseases, respiratory infections, sexually transmitted infections (STIs), and antimicrobial resistance (AMR).
Traditional molecular diagnostics have long been confined to centralized laboratories due to complexity, batch processing requirements, and the need for highly trained personnel. However, the advent of compact, cartridge-based systems—which allow sample-to-answer molecular results within 15–30 minutes—has transformed this landscape. Platforms such as Cepheid’s Xpert Xpress, Abbott’s ID NOW, and BioFire’s FilmArray 2.0 have proven their utility not just in labs but also in emergency departments, urgent care centers, and even mobile testing units.
The COVID-19 pandemic fast-tracked regulatory support and public adoption. Over 20 molecular POC platforms received Emergency Use Authorization (EUA) from the U.S. FDA during the pandemic. As of 2024, many of these devices have transitioned into full 510(k) approvals or CE-marked platforms, creating permanent diagnostic infrastructure at the point of need. Similar adoption patterns are being seen in India, South Korea, and parts of the EU, particularly for influenza, RSV, and tuberculosis.
Importantly, POC molecular tests provide faster clinical decision-making, especially in emergency settings where delays in diagnosis can affect outcomes. For example, rapid flu and COVID testing enable immediate antiviral initiation. STI tests such as Xpert CT/NG reduce the gap between diagnosis and treatment, minimizing transmission and patient dropout from follow-up.
The AMR crisis has further intensified the demand for rapid pathogen and resistance gene identification. POC molecular panels now enable detection of carbapenemase-producing organisms and MRSA within an hour, helping hospitals guide antibiotic use and isolate patients appropriately.
As multiplexing capabilities grow and turnaround time continues to shrink, the role of molecular POC testing is evolving from mere convenience to clinical necessity, particularly in infectious disease containment and emergency diagnostics.
Emergen Research is Offering a full report (Grab a Copy Now) @ https://www.emergenresearch.com/industry-report/molecular-diagnostics-point-of-care-market
Market Segmentation:
The report bifurcates the Molecular Diagnostics Point-of-Care market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
The molecular diagnostics POC market is increasingly shaped by platform convergence, miniaturization, and clinical workflow integration. Leading companies are expanding beyond infectious disease into oncology, prenatal genetics, and antimicrobial stewardship—while simultaneously reducing form factor, turnaround time, and training requirements.
Market leaders like Cepheid, Abbott, Roche, and BioFire are investing in next-gen POC systems that combine multiplex capability, cloud-based result delivery, and EMR integration. Their goal: shift diagnostics from centralized labs to the clinic, ambulance, and patient home, without sacrificing sensitivity.
Startups and new entrants are focusing on isothermal amplification, microfluidics, and mobile-device integration to create cost-effective, portable solutions for emerging markets and retail care. Meanwhile, AI-driven result interpretation and telehealth-compatible platforms are helping clinicians make decisions faster—even without an on-site lab technician.
Strategically, companies are pursuing partnerships with hospital systems, pharmacy chains, and national public health agencies to embed POC platforms into routine workflows and surveillance programs.
Some of the key companies in the global Molecular Diagnostics PoC market include:
- Abbott Laboratories
- Bayer Healthcare
- Roche Diagnostics
- Bio-Rad Laboratories
- Danaher Corporation
- BioMerieux
- Dako
- Abaxis Inc.
- OraSure Technologies Inc.
- Nipro Diagnostics
- Nuance Communications Inc.
Our goal at Emergen Research is to empower businesses with the knowledge and insights necessary to make informed decisions and thrive in today's dynamic business landscape. Our market research content is designed to equip professionals and organizations with comprehensive analyses, actionable recommendations, and a competitive edge to achieve their growth objectives.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/11
Target Audience of the Global Molecular Diagnostics Point-of-Care Market Report:
- Key Market Players
- Investors
- Venture capitalists
- Small- and medium-sized and large enterprises
- Third-party knowledge providers
- Value-Added Resellers (VARs)
- Global market producers, distributors, traders, and suppliers
- Research organizations, consulting companies, and various alliances interested in this sector
- Government bodies, independent regulatory authorities, and policymakers
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com